GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » 5-Year RORE %

Solvonis Therapeutics (LSE:SVNS) 5-Year RORE % : 0.00% (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Solvonis Therapeutics's 5-Year RORE % for the quarter that ended in Jun. 2024 was 0.00%.

The industry rank for Solvonis Therapeutics's 5-Year RORE % or its related term are showing as below:

LSE:SVNS's 5-Year RORE % is not ranked *
in the Industrial Products industry.
Industry Median: 10.69
* Ranked among companies with meaningful 5-Year RORE % only.

Solvonis Therapeutics 5-Year RORE % Historical Data

The historical data trend for Solvonis Therapeutics's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics 5-Year RORE % Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
5-Year RORE %
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Solvonis Therapeutics's 5-Year RORE %

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solvonis Therapeutics's 5-Year RORE % Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's 5-Year RORE % falls into.


;
;

Solvonis Therapeutics 5-Year RORE % Calculation

Solvonis Therapeutics's 5-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( - )/( -0.06-0 )
=/-0.06
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 5-year before.


Solvonis Therapeutics  (LSE:SVNS) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Solvonis Therapeutics 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Solvonis Therapeutics PLC, formerly Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines